Abstract:Huntington disease (HD) is a progressive autosomal dominant neurodegenerative disorder in which patients typically present with uncontrolled involuntary movements and subsequent cognitive decline. In 1993, a CAG trinucleotide repeat expansion in the coding region of the huntingtin (HTT) gene was identified as the cause of this disorder. This extended CAG repeat results in production of HTT protein with an expanded polyglutamine tract, leading to pathogenic HTT protein conformers that are resistant to protein turnover, culminating in cellular toxicity and neurodegeneration. Research into the mechanistic basis of HD has highlighted a role for bioenergetics abnormalities stemming from mitochondrial dysfunction, and for synaptic defects, including impaired neurotransmission and excitotoxicity. Interference with transcription regulation may underlie the mitochondrial dysfunction. Current therapies for HD are directed at treating symptoms, as there are no disease-modifying therapies. Commonly prescribed drugs for involuntary movement control include tetrabenazine, a potent and selective inhibitor of vesicular monoamine transporter 2 that depletes synaptic monoamines, and olanzapine, an atypical neuroleptic that blocks the dopamine D2 receptor. Various drugs are used to treat non-motor features. The HD therapeutic pipeline is robust, as numerous efforts are underway to identify disease-modifying treatments, with some small compounds and biological agents moving into clinical trials. Especially encouraging are dosage reduction strategies, including antisense oligonucleotides, and molecules directed at transcription dysregulation. Given the depth and breadth of current HD drug development efforts, there is reason to believe that disease-modifying therapies for HD will emerge, and this achievement will have profound implications for the entire neurotherapeutics field.

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

Progress in studies of gene therapy for Huntington's disease

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Huntington's Disease: Latest Frontiers in Therapeutics

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Therapy development in Huntington disease: From current strategies to emerging opportunities

Complex Pathogenesis and Therapeutic Strategies

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Emerging pharmacological approaches for Huntington's disease

Development of Novel Therapies for Huntington's Disease: Hope and Challenge1

Gene Targeting Techniques for Huntington’s Disease

CRISPR-Based Genome-Editing Tools for Huntington’s Disease Research and Therapy

Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities

Molecular Strategies to Target Protein Aggregation in Huntington's Disease

Advancements in surgical treatments for Huntington disease: From pallidotomy to experimental therapies

The molecular mechanisms of Huntington's disease and its advances in therapeutic strategies

Spliceosome-mediated RNA &Lt;i>trans</i>-Splicing: a Strategy for Huntington’s Disease Gene Therapy

Using gene or cell therapies to treat Huntington's disease